ERBB2 and breast cancer: As PEDF appears to be downregulated in post-menopausal ER+/HER2- BC bone metastasis [19] and NFκB-p65 regulation of PEDF in BC cells depends on menopausal oestrogen levels, we investigated the effects of PEDF and/or JSH-23 treatment on pro-metastatic biomarker expression under pre- and post-menopausal oestrogen conditions in MCF-7 and MDA-MB-231 cells (Figure 3).